Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases

Neurotoxicity Research

Volumn 5, Issue 3, 2003, Pages 183-199

  van der Stelt, Mario ^a   Hansen, Henrik H ^b,c   Veldhuis, Wouter B ^c,d   Bär, Peter R ^e   Nicolay, Klaas ^d   Veldink, Gerrit A ^a   Vliegenthart, Johannes F G ^a   Hansen, Harald S ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c HUMBOLDT UNIVERSITY   (Germany)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

2 Arachidonylglycerol; Anandamide; Endocannabinoids; Huntington's disease; Multiple sclerosis; Parkinson's disease; Tetrahydrocannabinol

Indexed keywords

CANNABINOID; ENDOCANNABINOID;

ACUTE DISEASE; ANIMAL; BIOSYNTHESIS; CHRONIC DISEASE; DEGENERATIVE DISEASE; DISEASE COURSE; HUMAN; METABOLISM; PATHOPHYSIOLOGY; REVIEW; SYNAPTIC TRANSMISSION;

ACUTE DISEASE; ANIMALS; CANNABINOIDS; CHRONIC DISEASE; DISEASE PROGRESSION; ENDOCANNABINOIDS; HUMANS; NEURODEGENERATIVE DISEASES; SYNAPTIC TRANSMISSION;

EID: 0037771394     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033139     Document Type: Review

References (148)

1. Abood ME, G Rizvi, N Sallapudi and SD McAllister (2001) Activation of the CB(1) Cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci. Lett. 309, 197-201.
2. Al-Hayani A, KN Wease, RA Ross, RG Pertwee and SN Davies (2001) The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice. Neuropharmacol. 41, 1000-1005.
3. Anderson JJ, AM Kash and TN Chase (1996) Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists. Eur. J. Pharmacol. 295, 163-168.
4. Andersson M, SO Jacobsson, KO Jonsson, G Tiger and CJ Fowler (2000) Neurotoxicity of glutamate in chick telencephalon neurons: Reduction of toxicity by preincubation with carbachol, but not by the endogenous fatty acid amides anandamide and palmitoylethanolamide. Arch. Toxicol. 74, 161-164.
5. Arreaza G, WA Devane, RL Omeir, G Sajnani, J Kunz, BF Cravatt and DG Deutsch (1997) The cloned rat hydrolytic enzyme responsible for the breakdown of anandamide also catalyzes its formation via the condesation of arachidonic acid and ethanolamine. Neurosci. Lett. 234, 59-62.
6. Baker D, G Pryce, JL Croxfor, P Brown, RG Pertwee, JW Huffman and L Layward (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404, 84-87.
7. Baker D, G Pryce, JL Croxford, P Brown, RG Pertwee, A Makriyannis, A Khanolkar, L Layward, F Fezza, T Bisogno and V Di Marzo (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15, 300-302.
8. + cells. Biochem. J. 346, 369-374.
9. Berrendero F, A Sanchez, A Cabranes, C Puerta, JA Ramos, A Gracia-Merino and J Fernandez-Ruiz (2001) Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 41, 195-202.
10. Bisogno T, N Sepe, D Melck, S Maurelli, L De Petrocellis and V Di Marzo (1997) Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem. J. 322, 671-677.
11. Bisogno T, F Berrendero, G Ambrosino, M Cebeira, JA Ramos JJ Fernández-Ruiz and V Di Marzo (1999a) Brain regional distribution of endocannabinoids: Implications for their biosynthesis and biological function. Biochem. Biophys. Res. Commun. 256, 377-380.
12. Bisogno T, D Melck, L De Petrocellis and V Di Marzo (1999b) Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. J. Neurochem. 72, 2113-2119.
13. Blandini F, G Nappi, C Tassorelli and E Martignoni (2000) Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog. Neurobiol. 62, 63-88.
14. Braida D, M Pozzi and M Sala (2000) CP 55, 940 protects against ischemia-induced electroencephalographic flattening and hyperlocomotion in Mongolian gerbils. Neurosci. Lett. 296, 69-72.
15. Breivogel CS, G Griffin, V Di Marzo and BR Martin (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60, 155-163.
16. Brooks JW, G Pryce, T Bisogno, SI Jaggar, DJ Hankey, P Brown, D Bridges, C Ledent, M Bifulco, AS Rice, V Di Marzo and D Baker (2002) Arvanil-induced inhibition of spasticity and persistent pain: Evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. Eur. J. Pharmacol. 439, 83-92.
17. Brotchie JM (1998) Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord. 13, 871-876.
18. Cadas H, S Schinelli and D Piomelli (1996a) Membrane localization of N -acylphosphatidylethanolamine in central neurons: Studies with exogenous phospholipases. J. Lipid Mediat. Cell Signal. 14, 63-70.
19. Cadas H, S Gaillet, M Beltramo, L Venance and D Piomelli (1996b) Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J. Neurosci 16, 3934-3942.
20. Cadas H, E di Tomaso and D Piomelli (1997) Occurrence and biosynthesis of endogenous cannabinoid precursor, N -arachidonoyl phosphatidylethanolamine, in rat brain. J. Neurosci 17, 1226-1242.
21. Calignano A, G La Rana, A Giuffrida and D Piomelli (1998) Control of pain initiation by endogenous cannabinoids. Nature 394, 277-281.
22. Carlisle SJ, F Marciano-Cabral, A Staab, C Ludwick and GA Gabral (2002) Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int. Immunopharmacol. 2, 69-82.
23. Chan GC, TR Hinds, S Impey and DR Storm (1998) Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J. Neurosci. 18, 5322-5332.
24. Craib SJ, HC Ellington, RG Pertwee and RA Ross (2001) A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. Br. J. Pharmacol. 134, 30-37.
25. Davies SN, RG Pertwee and G Riedel (2002) Functions of cannabinoid receptors in the hippocampus. Neuropharmacol. 42, 993-1007.
26. De Petrocellis L, T Bisogno, M Maccarrone, JB Davis, A Finazzi-Agro and V Di Marzo (2001) The activity of anandamide at vanilloid VR 1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem. 276, 12856-12863.
27. Denovan-Wright EM and HA Robertson (2000) Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience 98, 705-713.
28. Deutsch DG, ST Glaser, JM Howell, JS Kunz, RA Puffenbarger, CJ Hillard and N Abumrad (2000) The cellular uptake of anandamide is coupled to its breakdown by fatty acid amide hydrolase (FAAH). J. Biol. Chem. 276, 6967-6773.
29. Deutsch J, SI Rapoport and AD Purdon (1997) Relation between free fatty acid and acyl-CoA concentrations in rat brain following decapitation. Neurochem. Res. 22, 759-765.
30. Devane WA, L Hanus, A Breuer, RG Pertwee, LA Stevenson, G Griffin, D Gibson, A Mandelbaum, A Etinger and R Mechoulam (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
31. Di Marzo V, A Fontana, H Cadas, S Schinelli, G Cimino, J-C Schwartz and D Piomelli (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691.
32. Di Marzo V, D Melck, T Bisogno and L De Petrocellis (1999) Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 22, 80.
33. Di Marzo V, MP Hill, T Bisogno, AR Crossman and JM Brotchie (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 14, 1432-1438.
34. Diana MA, C Levenes, K mackie and A Marty (2002) Short-term retrograde inhibition of GABA ergic synaptic currents in rat purkinje cells is mediated by endogenous cannabinoids. J. Neurosci. 22, 200-208.
35. Dinh TP, D Carpenter, FM Leslie, TF Freund, I Katona, SL Sensi, S Kathuria and D Piomelli (2002) Brain monoacylglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA 99, 10819-10824.
36. Dirnagl U, C Iadecola and MA Moskowitz (1999) Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci. 22, 391-397.
37. Doble A (1999) The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol. Ther. 81, 163-221.
38. 1 receptor. NeuroReport 12, 3973-3978.
39. Egertova M, DK Giang, BF Cravatt and MR Elphick (1998) A new perspective on cannabinoid signalling: Complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc. R Soc. Lond. [Biol] 265, 2081-2085.
40. Facci L, R Dal Toso, S Romanello, A Buriani, SD Skaper and A Leon (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA 92, 3376-3380.
41. Farooqui AA, LA Horrocks and T Farooqui (2000) Glycerophospholipids in brain: Their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem. Phys. Lipids 106, 1-29.
42. Feigin A and D Zgaljardic (2002) Recent advances in Huntington's disease: Implications for experimental therapeutics. Curr. Opin. Neurol. 15, 483-489.
43. Felder C, A Nielsen, EM Briley, M Palkovits, J Priller, J Axelrod, DN Nguyen, JM Richardson, RM Riggin, GA Koppel, SM Paul and GW Becker (1996) Isolation and measurement of the end ogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 393, 231-235.
44. Fernandez-Ruiz J, I Lastres-Becker, A Cabranes, S Gonzalez and JA Ramos (2002) Endocannabinoids and basal ganglia functionality. Prostagl. Leukotr. Essent. Fatty Acids 66, 257-267.
45. Fowler CJ, K-O Jonsson and G Tiger (2001) Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide. Biochem. Pharmacol. 62, 517-526.
46. Fowler CJ and SOP Jacobsson (2002) Cellular transport of anandamide, 2-arachidonoylglycerol, and palmitoylethanolamide - targets for drug development? Prostagl. Leukotr. Essent. Fatty Acids 66, 193-200.
47. Frykholm P, L Hillered, B Långström, L Persson, J Valtysson, Y Watanabe and P Enblad (2001) Increase of interstitial glycerol reflects the degree of ischaemic brain damage: A PET and microdialysis study in a middle cerebral artery occlusion-reperfusion primate model. J. Neurol. Neurosurg. Psychiatr. 71, 455-461.
48. Gallily R, A Breuer and R Mechoulam (2000) 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur. J. Pharmacol. 406, R5-R7.
49. Gerdeman GL, J Ronesi and DM Lovinger (2002) Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat. Neurosci. 5, 446-451.
50. Giuffrida A, LH Parsons, TM Kerr, F Rodriguez de Fonseca, M Navarro and D Piomelli (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 2, 358-363.
51. Glass M (2001) The role of cannabinoids in neurodegenerative diseases. Prog. Neuropsychopharmacol. Biol. Psychiatr. 25, 743-765.
52. Glass M, M Dragunow and RL Faull (2000) The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97, 505-519.
53. Grant ER, AE Dubin, SP Zhang, RA Zivin and Z Zhong (2002) Simultaneous intracellular calcium and sodium flux imaging in human vanilloid receptor 1 (VR1)-transfected human embryonic kidney cells: A method to resolve ionic dependence of VR1-mediated cell death. J. Pharmacol. Exp. Ther. 300, 9-17.
54. Grundy RL, M Rabuffetti and M Beltramo (2001) Cannabinoids and neuroprotection. Mol. Neurobiol. 24, 29-51.
55. Gubellini P, B Picconi, M Bari, N Battista, P Calabresi, D Centonze, G Bernardi, A Finazzi-Agrò and M Maccarrone (2002) Experimental Parkinsonism alters endocannabinoid degradation: Implications for striatal glutamatergic transmission. J. Neurosci. 22, 6900-6907.
56. Guzman M, C Sanchez and I Galve-Roperh (2001) Control of the cell survival/death decision by cannabinoids. J. Mol. Med. 78, 613-625.
57. Hajos N, C Ledent and TF Freund (2001) Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106, 1-4.
58. Hampson AJ and M Grimaldi (2001) Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur. J. Neurosci. 13, 1529-1536.
59. Hampson RE, TC Foster and SA Deadwyler (1989) Effects of delta-9-tetrahydrocannabinol on sensory evoked hippocampal activity in the rat: Principal components analysis and sequential dependency. J. Pharmacol. Exp. Ther. 251, 870-877.
60. Hampson AJ, LM Bornheim, M Scanziani, CS Yost, AT Gray, BM Hansen, DJ Leonoudakis and PE Bickler (1998a) Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J. Neurochem. 70, 671-676.
61. Hampson AJ, M Grimaldi, J Axelrod and D Wink (1998b) Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA 95, 8268-8273.
62. Hansen HS, L Lauritzen, AM Strand, AM Vinggaard, A Frandsen and A Schousboe (1997) Characterization of glutamate-induced formation of N -acylphosphatidylethanolamine and N -acylethanolamine in cultured neocortical neurons. J. Neurochem. 69, 753-761.
63. Hansen HS, B Moesgaard, HH Hansen, A Schousboe and G Petersen (1999) Formation of N -acyl-phosphatidylethanolamine and N -acylethanolamine (including anandamide) during glutamate-induced neurotoxicity. Lipids 34, S327-S330.
64. Hansen HS, B Moesgaard, HH Hansen and G Petersen (2000) N -acylethanolamines and precursors - relation to cell injury. Chem. Phys. Lipids 108, 135-150.
65. Hansen HH, C Ikonomidou, P Bittigau, SH Hansen and HS Hansen (2001a) Accumulation of the anandamide precursor and other N -acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal cell death. J. Neurochem. 76, 39-46.
66. Hansen HH, PC Schmid, P Bittigau, I Lastres-Becker, F Berrendero, J Manzanares, C Ikonomidou, HHO Schmid, JJ Fernández-Ruiz and HS Hansen (2001b) Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem. 78, 1415-1427.
67. Hansen HH, I Azcoitia, S Pons, J Romero, LM Garcia-Segura, JA Ramos, HS Hansen and J Fernandez-Ruiz (2002) Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. J. Neurochem. 82, 154-158.
68. Hanus L, A Gopher, S Almog and R Mechoulam (1993) Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 36, 3032-3034.
69. Hanus L, S Abu-Lafi, E Fride, A Breuer, Z Vogel, DE Shalev, I Kustanovich and R Mechoulam (2001) 2-arachidonoyl glyceryl ether, an endogenous agonist of the cannabinoid CB 1 receptor. Proc. Natl. Acad. Sci. USA 98, 3662-3665.
70. Irving AJ, AA Coutts, J Harvey, MG Rae, K Mackie, GS Bewick and RG Pertwee (2000) Functional expression of cell surface cannabinoid CB 1 receptors on presynaptic inhibitory terminals in cultures rat hippocampal neurons. Neuroscience 98, 253-262.
71. Jin KL, XO Mao, PC Goldsmith and DA Greenberg (2000) CB 1 cannabinoid receptor induction in experimental stroke. Ann. Neurol. 48, 257-261.
72. Kerwin JL, AR Tuininga and LH Ericsson (1994) Identification of molecular species of glycerophospholipids and sphingomyelin using electrospray mass spectrometry. J. Lipid Res. 35, 1102-1114.
73. Killestein J, ELJ Hoogervorst, M Reif, NF Kalkers, AC van Loenen, PGM Staats, RW Gorter, BMJ Uitdehang and CH Polman (2002) Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 58, 1404-1407.
74. 2+ -dependent and-independent mechanisms. FEBS Lett. 429, 152-156.
75. Kreitzer AC and WG Regehr (2001) Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29, 717-727.
76. Lambert DG and V Di Marzo (1999) The palmitoylethanolamide and oleamide enigmas: Are these two fatty acid amides cannabimimetic? Curr. Med. Chem. 6, 757-773.
77. Lastres-Becker I, M Cebeira, ML de Ceballos, BY Zeng, P Jenner, JA Ramos and JJ Fernandez-Ruiz (2001a) Increased cannabinoid CB 1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur. J. Neurosci. 14, 1827-1832.
78. Lastres-Becker I, F Fezza, M Cebeira, T Bisogno, JA Ramos, A Milone, J Fernandez-Ruiz and VD Marzo (2001b) Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. NeuroReport 12, 2125-2129.
79. Lastres-Becker I, F Berrendero, JJ Lucas, E Martin-Aparicio, A Yamamoto, JA Ramos and JJ Fernandez-Ruiz (2002a) Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB (1) receptors in the basal ganglia of a transgenic model of Huntington's disease. Brain Res. 929, 236-242.
80. 1 receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease. Neurotoxicity Res. 4, 601-608.
81. Lastres-Becker I, HH Hansen, F Berrendero, R De Miguel, A Perez-Rosado, J Manzanares, JA Ramos and J Fernandez-Ruiz (2002c) Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse 44, 23-35.
82. Lee DP, AS Deonarine, M Kienetz, QS Zhu, M Skrzypczak, M Chan and PC Choy (2001) A novel pathway for lipid biosynthesis: The direct acylation of glycerol. J. Lipid Res. 42, 1979-1986.
83. Louw DF, FW Yang and GR Sutherland (2000) The effect of delta-9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res. 857, 183-187.
84. Lyman WD, JR Sonett, CF Brosnan, R Elkin and MB Bornstein (1989) Delta 9-tetrahydrocannabinol: A novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol. 23, 73-81.
85. Maccarrone M, T Lorenzon, M Bari, G Melino and A Finazzi-Agro (2000) Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem. 275, 31938-31945.
86. Mackie K, WA Devane and B Hille (1993) Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44, 498-500.
87. Maejima T, T Ohno-Shosaku and M Kano (2001) Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals. Neurosci. Res. 40, 205-210
88. Mailleux P and JJ Vanderhaeghen (1993) Dopaminergic regulation of cannabinoid receptor mRNA, levels in the rat caudate-putamen: An in situ hybridization study J. Neurochem. 61, 1705-1712.
89. Maingret, F, AJ Pate, M Lazdunski and E Honore (2001) The endocannabinoid mandamide is a direct and selective blocker of the background K(+) channel TASK-1. EMBO J. 20, 47-54.
90. Maneuf, YP, AR Crossman and IM Brotchie (1996a) Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55, 212-2. Synapse 22, 382-385.
91. Maneuf YP, JE Nash, AR Crossman and JM Brotchie (1996b) Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur. J. Pharmacol. 308, 161-164.
92. 1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Exp. Neurol., 148, 265-270.
93. Marsicano G, B Moosmann, H Hermann, B Lutz and C Behl (2002) Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J. Neurochem. 80, 448-456.
94. Mattson MP, W Duan, WA Pedersenanc, C Culmsee (2001) Neurodegenerative disorders and ischemic brain diseases. Apoptosis 6, 69-81.
95. Mauler F, J Mittendorf, E Horvath and J De Vry (2002) Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J. Pharmacol. Exp. Ther. 302, 359-368.
96. Mechoulam R, S Ben-Shabat, L Hanus, M Ligumsky, NE Kaminski, AR Schatz, A Gopher, S Almog, BR Martin, DR Compton, RG Pertwee, G Griffin, M Bayewitch, J Barg J and Z Vogel (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90.
97. Mechoulam R, D Panikashivili and E Shohami (2002) Cannabinoids and brain injury: Therapeutic implications. Trends Mol. Med. 8, 58-61.
98. Meschler JP, FA Clarkson, PJ Mathews, AC Howlett and BK Madras (2000) D(2), but not D(1) dopamine receptor agonists potentiate cannabinoid- induced sedation in nonhuman primates. J. Pharmacol. Exp. Ther. 292, 952-959.
99. Meschler JP, AC Howlett and BK Madras (2001) Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology (Berl.) 156, 79-85.
100. Mezey É. ZE Tóth, DN Cortright, MK Arzybi, JE Krause, R Elde, A Guo, PM Blumberg and A Szallasi (2000) Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc. Natl. Acad. Sci. USA 97, 3655-3660.
101. Moesgaard B, JW Jaroszewski and HS Hansen (1999) Accumulation of N -acyl-ethanolamine phospholipids in rat brains during postdecapitative ischemia: A 31 P NMR study. J. Lipid Res. 40, 515-521.
102. Moesgaard B, G Petersen, JW Jaroszewski and HS Hansen (2000) Age-dependent accumulation of N -acyl-ethanolamine phospholipids in ischemic rat brain: A 31 P NMR and enzyme activity study. J. Lipid Res. 41, 985-990.
103. Moesgaard B, G Petersen, SA Mortensen and HS Hansen (2002) Substantial species differences in relation to formation and degradation of N -acyl-ethanolamine phospholipids in heart tissue: An enzyme activity study. Comp. Biochem. Physiol. B 131, 475-482.
104. Muthian S and CJ Hillard (2000) CB1 receptor antagonists are neuroprotective in focal cerebral ischemia-reperfusion injury Symposium on the Cannabinoids (ICRS, Burlington, VT), p 107
105. Nagayama T, AD Sinor, RP Simon, J Chen, SH Graham, K Jin and DA Greenberg (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19, 2987-2995.
106. Natarajan V, PC Schmid, PV Reddy, ML Zuarte-Augustin and HHO Schmid (1983) Biosynthesis of N -acylethanolamine phospholipids by dog brain preparations. J. Neurochem. 41, 1303-1312.
107. Natarajan V, PC Schmid and HHO Schmid (1986) N -Acylethanolamine phospholipid metabolim in normal and ischemic rat brain. Biochim. Biophys. Acta 878, 32-41.
108. 2+-signals in cerebellar granule neurons in culture. J Neurosci. 19, 8765-8777.
109. Nicotera P, M Leist and L Manzo (1999) Neuronal cell death: A demise with different shapes. Trends, Pharmacol. Sci. 20, 46-51.
110. Page KJ, L Besret, M Jain, EM Monaghan, SB Dunnett and BJ Everitt (2000) Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia Exp. Brain Res. 130, 142-150.
111. Panikashvili D, C Simeonidou, S Ben-Shabat, L Hanus, A Breuer, R. Mechoulam and E Shohami (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury, Nature 413, 527-531.
112. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74, 129-180.
113. Petersen G and HS Hansen (1999) N -acylphosphatidylethanolamine-hydrolysing phospholipase D lacks the ability to transphosphatidylate. FEBS Lett. 455, 41-44.
114. Pitt D, P Werner and C Raine (2000) Glutamate excitotoxicity in a model of multiple sclerosis. Nature Med. 6, 67-70.
115. Borter AM, J-M Sauer MD Knierman, GW Becker, MJ Berna, J Bao, GG Nomikos, P Carter, FP Bymaster, AB Leese and CC Felder (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 301, 1020-1024.
116. Rakhshan F, TA Day, RD Blakely and EL Barker (2000) Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J. Pharmacol. Exp. Ther. 292, 3960-3967.
117. Rieckmann P and KJ Smith (2001) Multiple sclerosis: More than inflammation and demyelination Trends Neurosci. 24, 435-437.
118. Rodriguez de Fonseca F, MA Gorriti, A Bilbao, L Escuredo, LM Garcia-Segura, D Piomelli and M Navarro (2001) Role of the endogenous cannabinoid system as a modulator of dopamine transmission: Implications for Parkinson's disease and schizophrenia. Neurotoxicity Res. 3, 23-35.
119. Romero J, F Berrendero, A Perez-Rosado, J Manzanares, A Rojo, JJ Fernandez-Ruiz, JG de Yebenes and JA Ramos (2000) Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sci. 66, 485-494.
120. Ross RA, TM Gibson, HC Brockie, M Leslie, G Pashmi, SJ Craib, V Di Marzo and RG Pertwee (2001) Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br. J. Pharmacol. 132, 631-640.
121. Sanudo-Pena MC, SL Patrick, S Khen, RL Patrick, K Tsou and JM Walker (1998) Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease. Neurosci. Lett, 248, 171-174.
122. Schlicker E and M Kathmann (2001) Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22, 565-572.
123. Schmid PC, PV Reddy, V. Natarajan and HHO Schmid (1983) Metabolism of N -acylethanolamine phospholipids by mammalian phosphodiesterase of the phospholipase D type. J. Biol. Chem 258, 9302-9306.
124. Schmid PC, RJ Krebsbach, SR Perry, TM Dettmer, JL Maasson and HHO Schmid (1995) Occurrence and postmortem generation of anandamide and other long-chain N -acylethanolamines in mammalian brain. FEBS Lett. 375, 117-120. Erratum appears in FEBS Lett 385: 125, 1996.
125. Shen M and SA Thayer (1998a) Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 54, 459-462.
126. Shen M and SA Thayer (1998b) The cannabinoid agonist Win 55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. Brain Res. 783, 77-84.
127. 2+ channel. Eur. J. Pharmacol. 296, 347-350.
128. Sieradzan KA, SH Fox, M Hill, JP Dick, AR Crossman and JM Brotchie (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: A pilot study. Neurology 57, 2108-2111.
129. Silverdale MA, S McGuire, A McInnes, AR Crossman and JM Brotchie (2001) Striatal cannabinoid CB receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp. Neurol. 169, 400-406.
130. Sinor AD, SM Irvin and DA Greenberg (2000) Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci. Lett. 278, 157-160.
131. Skaper SD, A Buriani, R Dal Toso, L Petrelli, S Romanello, L Facci and A Leon (1996) The aliamide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. USA 93, 3984-3989.
132. Stella N and D Piomelli (2001) Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur. J. Pharmacol. 425, 189-196.
133. Stella N, P Schweitzer and D Piomelli (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature, 388, 773-778.
134. Sugiura T, S Kondo, A Sukagawa, T Tonegawa, S Nakane, A Yamashita, Y Ishima and K Waku (1996) Transacylase-mediated and phosphodiesterase-mediated synthesis of N -arachidonoylethanolamine, an endogenous cannabinoid- receptor lig-and, in rat brain microsomes-Comparison with synthesis from free arachidonic acid and ethanolamine. Eur. J. Biochem. 240, 53-62.
135. Sugiura T, Y Kobayashi, S Oka and K Waku (2002) Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological relevance. Prostagl. Leukotr. Essent. Fatty Acids 66, 173-192.
136. Tsou K, S Brown, MC Sanudo-Peña, K Mackie and IM Walker (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83, 393-411.
137. Tsou K, K Mackie, MC Sañudo-Peña and JM Walker (1999) Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience 93, 969-975.
138. van der Stelt M, WB Veldhuis, PR Bar, GA Veldink, JF Vliegenthart and K Nicolay (2001a) Neuroprotection by Delta 9-tetrahydrocannabinol the main active compound in marijuana, against oubrain-induced in vivo excitotoxicity. J. Neurosci. 21, 6475-6479.
139. van der Stelt, M, WB Veldhuis, GW van Haaften, F Fezza, T Bisogno, PR Bar, GA Veldink, JF Vliegenthart, V Di Marzo and K Nicolay (2001b) Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. 21, 8765-8777.
140. van der Stelt M, WB Veldhuis, M Maccarrone, PR Bär, K Nicolay, GA Veldink, V Di Marzo and JFG Vliegenthart (2002) Acute neuronal injury; excitotoxicity and the endocamnabinoid system. Mol. Neurobiol. 26, 317-346.
141. Varma N, GC Carlson, C Ledent and BE Alge (2001) Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J. Neurochem. 21, 1-5.
142. Venance L, D Piomelli, J Glowinski and C Giaume (1995) Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature 376, 590-594.
143. Venters HD, R Dantzer and KW Kelley (2000) A new concept in neurodegeneration: TNFalpha is a silencer of survival signals. Trends Neurosci. 23, 175-180.
144. Walker JM, SM Huang, NM Strangman, K Tsou and MC Sañudo-Peña (1999) Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. USA 96, 12198-12203.
145. Wirguin I, R Mechoulam, A Breuer, E Schezen, J Weidenfeld and T Brenner (1994) Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacol. 28, 209-214.
146. Zeng BY, B Dass, A Owen, S Rose, C Cannizzaro, BC Tel and P Jenner (1999) Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neurosci. Lett. 276, 71-74.
147. Zygmunt PM, J Petersson, DA Andersson, H Chuang, M Sorgard, V Di Marzo, D Julius and ED Hogestatt (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-457.
148. Zygmunt PM, H Chuang H, P Movahed D Julius and ED Hogestatt (2000) The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur. J. Pharmacol. 396, 39-42.